- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Collaboration to explore nilotinib as a potential treatment for Parkinson’s
13 July 2016 • Author: Victoria White, Digital Content Producer
A new collaboration is set to investigate nilotinib, a chronic myelogenous leukaemia drug, as a potential treatment for Parkinson’s disease.
The Michael J. Fox Foundation for Parkinson’s Research (MJFF), Van Andel Research Institute (VARI) and The Cure Parkinson’s Trust (CPT) are to design a therapeutic development programme including a double-blind, placebo-controlled clinical trial of nilotinib expected to begin in 2017.
The goal of the collaboration is to initially advance the therapy as a potentially disease-modifying and/or symptomatic Parkinson’s treatment by expanding on early safety findings in order to better understand the implications of long-term use of nilotinib in non-cancer patients.
The programme will also address early-stage preclinical and clinical findings about the drug. Earlier studies have demonstrated some preliminary data on measures of drug penetration into the brain (as measured in spinal fluid) and exploratory biochemical measures. The new study aims to verify and expand on these findings.
Inhibiting the activity of c-Abl
The role of c-Abl as a cancer driver in myelogous leukaemia is well known and it may also play a role in Parkinson’s disease. Preclinical studies have shown that nilotinib may protect neuronal cells from Parkinson’s pathology by inhibiting the activity of c-Abl, but additional work is required to understand the relationship between nilotinib dosing and c-Abl activity. The study also aims to explore and independently verify the drug’s potential to treat Parkinson’s symptoms.
Commenting on the collaboration, Todd Sherer, PhD, chief executive officer of MJFF, said: “We are enthusiastic about further investigating early clinical results that indicated some level of nilotinib safety and tolerability in Parkinson’s patients.”
Tom Isaacs, co-founder of The Cure Parkinson’s Trust, added: “It is imperative that we work urgently with the Parkinson’s community — my fellow patients as well as drug developers — as we continue vetting nilotinib’s potential to address the medical needs of people with Parkinson’s in a safe and effective manner.”
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Butterworth Laboratories Ltd CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe Kaiser Optical Systems Inc. L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics